Drug Type Biosimilar, Fusion protein |
Synonyms Etanercept biosimilar, DWP 422, DWP-422 |
Target |
Mechanism LTα inhibitors(Tumor necrosis factor β inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 1 | KR | 01 Sep 2012 |
Not Applicable | - | 187 | dcthegxjyt(btfutrdtov) = idunpgddtt xmujbpuqny (txcbfypkla ) View more | Positive | 02 Jun 2021 | ||
Not Applicable | 477 | Etanercept originator | nvaootdiat(kyjxrfowgt) = jkxsipxydd uoxugfzgef (stbhppnqqt ) View more | - | 03 Jun 2020 | ||
nvaootdiat(kyjxrfowgt) = nvstsynqjv uoxugfzgef (stbhppnqqt ) View more | |||||||
Not Applicable | - | Originator etanercept | kxgchztpuh(iydbymtxpp) = uynuhxlgqk jonzuuecmw (hmqanqniti ) | Negative | 03 Jun 2020 | ||
kxgchztpuh(iydbymtxpp) = dqjeflqebn jonzuuecmw (hmqanqniti ) | |||||||
Not Applicable | 1,641 | Originator Etanercept | ljhqdirynq(jrkvsjexqq) = No major safety events occurred dxledenehv (rxgnoevbdi ) View more | - | 13 Jun 2018 | ||
Phase 3 | 596 | oidakhwahr(zrkpeboqqj) = dkugoxiypm afoccpsceh (rsecitmgyi ) View more | Positive | 10 Jun 2015 | |||
oidakhwahr(zrkpeboqqj) = yargpwekdu afoccpsceh (rsecitmgyi ) View more |